SUPRAX CHEWABLE TABLETS Rx
Generic Name and Formulations:
Cefixime 100mg, 150mg, 200mg; chew tabs; contains phenylalanine.
Lupin Pharmaceuticals, Inc.
Indications for SUPRAX CHEWABLE TABLETS:
Susceptible infections, including otitis media, pharyngitis, tonsillitis, acute exacerbation of chronic bronchitis; uncomplicated UTIs and cervical or urethral gonorrhea.
400mg once daily or 200mg every 12 hrs. Gonorrhea: 400mg once. Infections due to Streptococcus pyogenes: treat for at least 10 days. Renal impairment: adjust dose; see full labeling.
<6 months: not established. Chew tabs: chew or crush before swallowing. <50kg and 6 months–12yrs: 8mg/kg once daily or 4mg/kg every 12 hrs. >50kg or >12yrs: use adult dose. Otitis media: treat with chew tabs or susp; do not substitute with tabs. Infections due to Streptococcus pyogenes: treat for at least 10 days.
Penicillin or other allergy. Renal impairment. History of GI disease. Chew tabs: phenylketonuria. Labor and delivery. Pregnancy (Cat.B). Nursing mothers.
May potentiate carbamazepine, anticoagulants (eg, warfarin) (monitor). May cause false (+) Clinitest, direct Coomb's, nitroprusside test for ketones. Potentiated by probenecid.
Diarrhea, nausea, loose stools, abdominal pain, dyspepsia, vomiting, hypersensitivity reactions, headache, dizziness, seizures, transient renal and hepatic effects; C. difficile-associated diarrhea.
Tabs—10, 50, 100; Chew tabs—10, 50; Susp 100mg/5mL—50mL, 75mL, 100mL; 200mg/5mL—25mL, 37.5mL, 50mL, 75mL, 100mL; 500mg/5mL—10mL, 20mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities